Routine assessment of GlycA in addition to Lp(a) and hs-CRP may help to identify individuals at particularly increased CVD risk who may benefit from more aggressive preventive therapies.
P. Garg, Wei-Hua Guan, Sarah O. Nomura et al.· Journal of the American Hear...· 0 citations
BACKGROUND
Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease.
SOURCES OF MATERIAL
Literature review.
ABSTRACT OF FINDINGS
A large body of evidence has established the association between Lp(a) and subclinical atherosclerosis. In particular, Lp(a) is associated with coronary a...
Apurva Khedagi, Yu-Si Gong, G. Dharmavaram et al.· Journal of Clinical Lipidolo...· 0 citations
This review examines the role of elevated Lp(a) in premature cardiovascular events, including premature myocardial infarction, stroke, and peripheral arterial disease, and highlights the importance Lp(a) testing may play in secondary prevention, focusing on cascade screening for elevated Lp(a) in relatives of affected...
M. Safarova, Laurence S. Sperling, Anurag Mehta et al.· European Journal of Preventi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.